BRPI0719790A2 - Derivados de imidazolonas, o preparo a título de medicamentos, composições farmacêuticas, utilização como inibidores de proteínas quinases, notadamente cdc7 - Google Patents

Derivados de imidazolonas, o preparo a título de medicamentos, composições farmacêuticas, utilização como inibidores de proteínas quinases, notadamente cdc7

Info

Publication number
BRPI0719790A2
BRPI0719790A2 BRPI0719790-0A2A BRPI0719790A BRPI0719790A2 BR PI0719790 A2 BRPI0719790 A2 BR PI0719790A2 BR PI0719790 A BRPI0719790 A BR PI0719790A BR PI0719790 A2 BRPI0719790 A2 BR PI0719790A2
Authority
BR
Brazil
Prior art keywords
immedazolon
derivatives
preparation
pharmaceutical compositions
protein kinase
Prior art date
Application number
BRPI0719790-0A2A
Other languages
English (en)
Inventor
Vincent Leroy
Eric Bacque
Emmanuel Conseile
Anke Steinmetz
Baptiste Ronan
Jean-Philippe Letallec
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of BRPI0719790A2 publication Critical patent/BRPI0719790A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Vascular Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
BRPI0719790-0A2A 2006-10-12 2007-10-10 Derivados de imidazolonas, o preparo a título de medicamentos, composições farmacêuticas, utilização como inibidores de proteínas quinases, notadamente cdc7 BRPI0719790A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0608924A FR2907120B1 (fr) 2006-10-12 2006-10-12 Nouveaux derives imidazolones,leur preparation a titre de medicaments,compositions pharmaceutiques,utilisation comme inhibiteurs de proteines kinases notamment cdc7
PCT/FR2007/001651 WO2008046982A2 (fr) 2006-10-12 2007-10-10 Nouveaux derives imidazolones, leur preparation a titre de medicaments, compositions pharmaceutiques, utilisation comme inhibiteurs de proteines kinases notamment cdc7

Publications (1)

Publication Number Publication Date
BRPI0719790A2 true BRPI0719790A2 (pt) 2014-11-25

Family

ID=37964098

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0719790-0A2A BRPI0719790A2 (pt) 2006-10-12 2007-10-10 Derivados de imidazolonas, o preparo a título de medicamentos, composições farmacêuticas, utilização como inibidores de proteínas quinases, notadamente cdc7

Country Status (29)

Country Link
US (1) US8314121B2 (pt)
EP (1) EP2094699B1 (pt)
JP (1) JP2010505922A (pt)
KR (1) KR101552361B1 (pt)
CN (1) CN101522678A (pt)
AR (1) AR063249A1 (pt)
AT (1) ATE517105T1 (pt)
AU (1) AU2007311833B2 (pt)
BR (1) BRPI0719790A2 (pt)
CA (1) CA2660166C (pt)
CL (1) CL2007002934A1 (pt)
CO (1) CO6160310A2 (pt)
CY (1) CY1112066T1 (pt)
DK (1) DK2094699T3 (pt)
EA (1) EA018496B1 (pt)
ES (1) ES2370049T3 (pt)
FR (1) FR2907120B1 (pt)
HR (1) HRP20110759T1 (pt)
IL (1) IL197452A (pt)
MA (1) MA30877B1 (pt)
MX (1) MX2009003283A (pt)
NO (1) NO20091486L (pt)
PL (1) PL2094699T3 (pt)
PT (1) PT2094699E (pt)
RS (1) RS51985B (pt)
SI (1) SI2094699T1 (pt)
TW (1) TW200821310A (pt)
UY (1) UY30642A1 (pt)
WO (1) WO2008046982A2 (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010122979A1 (ja) 2009-04-20 2010-10-28 Ｓｂｉバイオテック株式会社 チアゾリジノン誘導体
US8435980B2 (en) 2009-07-15 2013-05-07 Abbvie Inc. Pyrrolopyridine inhibitors of kinases
PL2509602T3 (pl) * 2009-12-04 2017-08-31 Senhwa Biosciences, Inc. Pirazolopirymidyny i podobne heterocykle jako inhibitory ck2
EP2560971B1 (en) 2010-04-19 2014-04-09 Abbvie Inc. Pyrrolopyridines as inhibitors of kinases
MX344474B (es) * 2011-03-31 2016-12-16 Carna Biosciences Inc Nuevos derivados de furanona.
US9974795B2 (en) 2014-01-31 2018-05-22 Carna Biosciences, Inc. Anticancer agent composition
GB201807147D0 (en) 2018-05-01 2018-06-13 Oncologica Uk Ltd Therapeutic combination
CA3113621A1 (en) 2018-09-24 2020-04-02 Sierra Oncology, Inc. Methods of treatment of cancer comprising cdc7 inhibitors
EP4083037A4 (en) * 2019-12-26 2024-01-24 Yonsei University, University-Industry Foundation(UIF). Pyrrolidine derivative, and pharmaceutical composition for preventing or treating beta-amyloid or tau protein-associated diseases containing same

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6335342B1 (en) 2000-06-19 2002-01-01 Pharmacia & Upjohn S.P.A. Azaindole derivatives, process for their preparation, and their use as antitumor agents
US7432375B2 (en) 2003-03-06 2008-10-07 Eisai R & D Management Co., Ltd. JNK inhibitors
WO2005014572A1 (en) * 2003-08-08 2005-02-17 Pharmacia Italia S.P.A. Pyrimidylpyrrole derivatives active as kinase inhibitors
US7514448B2 (en) 2004-04-02 2009-04-07 Vertex Pharmaceuticals Incorporated Azaindoles useful as inhibitors of rock and other protein kinases
BRPI0518158A (pt) * 2004-10-14 2008-11-04 Hoffmann La Roche tiazolinonas de azaindol como agentes anti-cáncer
US7371862B2 (en) * 2005-11-11 2008-05-13 Pfizer Italia S.R.L. Azaindolylidene derivatives as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them

Also Published As

Publication number Publication date
CO6160310A2 (es) 2010-05-20
EP2094699A2 (fr) 2009-09-02
KR20090064571A (ko) 2009-06-19
AU2007311833B2 (en) 2013-05-02
US8314121B2 (en) 2012-11-20
FR2907120B1 (fr) 2013-01-11
PT2094699E (pt) 2011-10-24
CA2660166A1 (fr) 2008-04-24
EA200970364A1 (ru) 2009-10-30
IL197452A0 (en) 2009-12-24
CN101522678A (zh) 2009-09-02
SI2094699T1 (sl) 2011-11-30
CY1112066T1 (el) 2015-11-04
RS51985B (sr) 2012-02-29
WO2008046982A2 (fr) 2008-04-24
ATE517105T1 (de) 2011-08-15
CL2007002934A1 (es) 2008-05-30
AU2007311833A1 (en) 2008-04-24
MX2009003283A (es) 2009-04-08
EA018496B1 (ru) 2013-08-30
TW200821310A (en) 2008-05-16
HRP20110759T1 (hr) 2011-11-30
DK2094699T3 (da) 2011-11-07
UY30642A1 (es) 2008-05-31
JP2010505922A (ja) 2010-02-25
AR063249A1 (es) 2009-01-14
FR2907120A1 (fr) 2008-04-18
WO2008046982A3 (fr) 2008-06-19
EP2094699B1 (fr) 2011-07-20
US20090253679A1 (en) 2009-10-08
IL197452A (en) 2015-10-29
PL2094699T3 (pl) 2011-12-30
ES2370049T3 (es) 2011-12-12
CA2660166C (fr) 2015-12-29
MA30877B1 (fr) 2009-11-02
NO20091486L (no) 2009-04-16
KR101552361B1 (ko) 2015-09-10

Similar Documents

Publication Publication Date Title
BRPI0815606A2 (pt) Derivados de 6-triazol piridazina - sulfanil benzotiazol e benzimidazol, o respectivo processo de preparo, a respectiva aplicação a título de medicamentos, composições farmacêuticas e utilização, notadamente como inibidores de met.
IL192845A (en) The history of benzamide and the trower, a process for making them and their pharmaceutical preparations
DK2010190T3 (da) Farmaceutisk opløsningsformulering til tryksatte, dosisregulerede inhalatorer
IL203292A (en) History of n-indazolil affluent, process for preparation, intermediates obtained in this process and pharmacological preparations containing the history
IL206394A (en) Derivatives of 2-Benzylpyridine Filtration as Met Kinase Inhibitors, Process for their Preparation, Medication and Use
DK2399579T3 (da) Farmaceutiske doseringsformer
BRPI1009324A2 (pt) compostos e/ou farmaceuticamente aceitáveis dos mesmos, composição farmacêutica e respectivos usos
IL192440A0 (en) Sulphur-containing cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors
IL215065A (en) Proline derivatives, their preparation process, their pharmaceutical compositions and their uses in drug preparation
BRPI0915897A2 (pt) compostos derivados triazóis, composições farmacêuticas e combinações dos mesmos e seus usos
BRPI1010621A2 (pt) derivado de imidazoquinolinonas, sua composição farmacêutica e seu uso
IL207512A0 (en) Pharmaceutical composition for poorly soluble drugs
IL208203A (en) Annotations of 3,2-Dihydro-Pyrido-4,1-Exazine and 3,2-Dihydro-4-Oxa-9,1-Diazapananthrene, Preparation Processes and Pharmaceutical Preparations
IL211018A (en) Inhibitors, processes for making them, medicinal preparations containing them and their use
IL192826A0 (en) Thiazole derivatives, their preparation and pharmaceutical compositions containing them
IL192442A0 (en) Novel cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors
IL195813A0 (en) Substituted aminopyrazolopyridines and salts thereof, their preparations and pharmaceutical compositions comprising them
DK2107055T3 (da) Dosmetinderivater, fremgangsmåde til fremstilling heraf og farmaceutiske sammensætninger indeholdende disse
BRPI0915552A2 (pt) derivados de ciclosporina, seu uso e sua composição farmacêutica
IL197452A0 (en) New imidazolone derivatives, preparation thereof as drugs, pharmaceutical compositions, and use thereof as protein kinase inhibitors, in particular cdc7
BRPI0907228A2 (pt) Compostos de tienopiridazina, suas preparações, composições farmacêuticas e usos
BRPI0908336A2 (pt) Compostos derivados de azetidinas, o respectivo preparo e a respectiva aplicação em terapêutica, medicamentos e composições farmacêuticas compreendendo os mesmos
EP2193795A4 (en) AQUEOUS PHARMACEUTICAL COMPOSITION CONTAINING LATANOPROST
ZA200900237B (en) Substituted aminopyrazolopyridines and salts thereof, their preparations and pharmaceutical compositions comprising them
BRPI0819202A2 (pt) Derivado heterocíclico, e, composição farmacêutica

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2483 DE 07-08-2018 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.